Andrew G Sikora

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide
    Amy Chu
    Department of Otolaryngology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1189, New York, New York 10029, USA
    Oncologist 18:180-9. 2013
  2. ncbi Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy
    Andrew G Sikora
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:1834-44. 2010
  3. ncbi Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release
    Padmini Jayaraman
    Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY 10028, USA
    J Immunol 188:5365-76. 2012
  4. ncbi Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
    Charles C L Tong
    Department of Otolaryngology, Head and Neck Surgery, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1189, New York, NY, USA
    Immunol Res 54:266-74. 2012
  5. ncbi IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity
    Andrew G Sikora
    Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 182:7398-407. 2009
  6. ncbi Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy
    Charles C L Tong
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Oncol Rep 27:1580-6. 2012
  7. ncbi Conference scene: immune effector mechanisms in tumor immunity
    Andrew G Sikora
    Departments of Otolaryngology, Immunology, Oncological Sciences and Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Immunotherapy 4:141-3. 2012
  8. ncbi Predictors of survival in mucosal melanoma of the head and neck
    Daniel Jethanamest
    Department of Otolaryngology Head and Neck Surgery, New York University School of Medicine, New York, NY, USA
    Ann Surg Oncol 18:2748-56. 2011
  9. ncbi Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice
    Chengwen Liu
    Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1165-75. 2008

Collaborators

Detail Information

Publications9

  1. ncbi A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide
    Amy Chu
    Department of Otolaryngology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1189, New York, New York 10029, USA
    Oncologist 18:180-9. 2013
    ..Based on the current state of the literature, this article is intended to be a reference for physicians to effectively manage psychosocial outcomes when diagnosing patients with HPV-associated OPC...
  2. ncbi Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy
    Andrew G Sikora
    Department of Melanoma Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:1834-44. 2010
    ..We tested the hypothesis that targeted iNOS inhibition would interfere with human melanoma growth and survival in vivo in a preclinical model...
  3. ncbi Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release
    Padmini Jayaraman
    Department of Otolaryngology, Mount Sinai School of Medicine, New York, NY 10028, USA
    J Immunol 188:5365-76. 2012
    ..These data suggest a critical role for tumor-expressed iNOS in the recruitment and induction of functional MDSC by modulation of tumor VEGF secretion and upregulation of STAT3 and ROS in MDSC...
  4. ncbi Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
    Charles C L Tong
    Department of Otolaryngology, Head and Neck Surgery, The Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1189, New York, NY, USA
    Immunol Res 54:266-74. 2012
    ..This article outlines significant immune-suppressive mechanisms in the HNSCC tumor microenvironment and potential approaches to enhancing the antitumor immune response...
  5. ncbi IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity
    Andrew G Sikora
    Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 182:7398-407. 2009
    ....
  6. ncbi Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy
    Charles C L Tong
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Oncol Rep 27:1580-6. 2012
    ..The most common grade 3-4 toxicities were mucositis (46%), leukopenia (18%), anemia (18%) and dermatitis (17%). Concurrent 5-FU, HU, cetuximab and SIB-IMRT is a highly active regimen, particularly in patients with p16-positive disease...
  7. ncbi Conference scene: immune effector mechanisms in tumor immunity
    Andrew G Sikora
    Departments of Otolaryngology, Immunology, Oncological Sciences and Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Immunotherapy 4:141-3. 2012
    ..The conference built on these early successes and aimed to push further into the uncharted territories of successful cancer immunotherapy...
  8. ncbi Predictors of survival in mucosal melanoma of the head and neck
    Daniel Jethanamest
    Department of Otolaryngology Head and Neck Surgery, New York University School of Medicine, New York, NY, USA
    Ann Surg Oncol 18:2748-56. 2011
    ..In order to identify factors predictive of survival, we analyzed MMHN outcomes in a large US cohort...
  9. ncbi Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice
    Chengwen Liu
    Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:1165-75. 2008
    ..Our data thus demonstrated that activated pDCs are capable of initiating effective and systemic antitumor immunity through the orchestration of an immune cascade involving the sequential activation of NK cells, cDCs, and CD8(+) T cells...